Full Press Release Details
Pharmaceuticals to Present at the 8th National Life Science &
Week ILSI-BIOMED Conference, Israel 2009
Israel - June 10, 2009 - Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB; www.oramed.com),
a developer of oral delivery systems, announced that Oramed was chosen to
present at the 8th National Life Science & Technology Week ILSI-BIOMED
Conference, Israel 2009. The presentation will be given by Mr. Nadav
Kidron, President and CEO of Oramed, on Tuesday, June 16th during
the BioPharma Session at 12:30 p.m. (local time) at the David Intercontinental
Hotel in Tel-Aviv, Israel.
"The selection of Oramed as one
of the companies to present at the ILSI-Biomed is a great opportunity that
allows us to present our company to the leading biomedical, health care and life
science professionals from all over the world," said Nadav Kidron, Oramed CEO.
For more information about the upcoming
ILSI Biomed conference, please visit http://www2.kenes.com/biomed/Pages/Home.aspx
Oramed Pharmaceuticals
Pharmaceuticals is a technology pioneer in the field of oral delivery solutions
for drugs and vaccines presently delivered via injection. Oramed is
seeking to revolutionize the treatment of diabetes through its patented flagship
product, an orally ingestible insulin capsule currently in phase 2 clinical
trials. Established in 2006, Oramed's technology is based on over 25 years of
research by top research scientists at Jerusalem's Hadassah Medical Center. The
Company's corporate and R&D headquarters are based in
information, please visit www.oramed.com
the statements contained in this press release are forward-looking statements
which involve known and unknown risks, uncertainties and other factors which may
cause the actual results, performance or achievements of the company, or
industry results, to be materially different from any future results,
performance or achievements expressed or implied by such forward looking
statements, including the risks and uncertainties related to the progress,
timing, cost, and results of clinical trials and product development programs;
difficulties or delays in obtaining regulatory approval for our product
candidates; competition from other pharmaceutical or biotechnology companies;
and the company's ability to obtain additional funding required to conduct its
research, development and commercialization activities. Please refer to the
company's filings with the Securities and Exchange Commission for a
comprehensive list of risk factors that could cause actual results, performance
or achievements of the company to differ materially from those
expressed or implied in such forward looking statements. The company undertakes
no obligation to update or revise any forward-looking statements.
and Business Development Contacts:
Email: tara@oramed.com